Abstract: A pharmaceutical composition including particles each containing a water-soluble base material and a poorly water-soluble compound, the water-soluble base material containing a rapidly water-soluble compound, wherein the poorly water-soluble compound is a kinase inhibitor and exists in an amorphous state in the water-soluble base material.

Abstract: The vehicle seat includes a cushion material in which a soft pad and a hard pad having different hardness from each other are combined. The soft pad is provided with an engagement protrusion protruding toward the hard pad, and the hard pad is provided with a recessed portion receiving the engagement protrusion. The recessed portion has a wall surface extending in a direction intersecting an assembling direction of the soft pad and the hard pad. One of the wall surface and the engagement protrusion includes a protruding portion, and another of the wall surface and the engagement protrusion includes an engagement portion which engages with the protruding portion. The protruding portion and the engagement portion are engaged with each other to restrict relative movement between the soft pad and the hard pad in the assembling direction.

Abstract: A cushion pad of a vehicle seat including: a cushion member including a soft pad and a hard pad which is harder than the soft pad, the soft pad being integrated with the hard pad so as to wrap the hard pad without covering a mounting side surface of the hard pad, wherein a groove, which is opened to the mounting side and having a size large enough to receive an exuding piece generated during molding of the soft pad, is provided in a periphery of the mounting side surface of the hard pad.

Abstract: A cushion pad of a vehicle seat including: a cushion member including a soft pad and a hard pad which is harder than the soft pad, the soft pad being integrated with the hard pad so as to wrap the hard pad without covering a mounting side surface of the hard pad, wherein a groove, which is opened to the mounting side and having a size large enough to receive an exuding piece generated during molding of the soft pad, is provided in a periphery of the mounting side surface of the hard pad.

Abstract: Swine Toll-like receptor 9 (TLR9)-expressing cells are prepared by cloning a TLR9 gene from swine intestinal Peyer's patches. Functional analysis on CpG DNAs using the above cells revealed that swine TLR9 shows a higher recognition ability for a human CpG DNA motif (CpG2006) than for a mouse-specific CpG DNA motif (CpG1826). When the mRNA expression levels in various tissues are compared by the real-time PCR method, it is found out that the mRNA is expressed in Peyer's patches and mesenteric lymph nodes, which play important roles in the intestinal tract immune system, at a level thrice as much as in spleen or more. Thus, the cells expressing an intestinal tract tissue-expressed TLR (for example, TLR9) can be used to identify samples capable of activating the intestinal tract immune system.

Abstract: Cells with forced expression of swine Toll-like receptor 9 (TLR9) are prepared by cloning a TLR9 gene from swine intestinal Peyer's patches. Functional analysis on CpG DNAs using the above cells revealed that swine TLR9 shows a higher recognition ability for a human CpG DNA motif (CpG2006) than for a mouse-specific CpG DNA motif (CpG1826). When the mRNA expression levels in various tissues are compared by the real-time PCR method, it is found out that the mRNA is expressed in Peyer's patches and mesenteric lymph nodes, which play important roles in the intestinal tract immune system, at a level thrice as much as in spleen or more. Thus, the cells that are forced to express an intestinal tract tissue-expressed TLR (for example, TLR9) can be used to identify samples capable of activating the intestinal tract immune system.